Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT04310709 | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma(RENOBATE) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05517239 | Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment(PEACH) | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02141906 | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin | completed | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05502458 | Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03163992 | Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | completed | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT00247728 | PI-88 in Hepatocellular Carcinoma After Hepatectomy | completed | Phase 2 | 172 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT02178358 | A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 132 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 25, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01900002 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT00844883 | Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT02973516 | Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis | completed | Phase 2 | 41 | GuerbetINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tiziana Life Sciences LTDINDUSTRY | 3 | Oct 12, 2021 | clinicaltrials |
| NCT00914355 | Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) | completed | Phase 2 | 92 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02089763 | Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
| NCT00261378 | Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation(PRECISIONV) | completed | Phase 2 | 212 | Boston Scientific CorporationINDUSTRY | 4 | Jul 21, 2021 | clinicaltrials |
| NCT03245190 | Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 27 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT01033240 | CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer | completed | Phase 2 | 172 | Daiichi SankyoINDUSTRY | 4 | Apr 8, 2021 | clinicaltrials |
| NCT01915589 | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 16 | BayerINDUSTRY | 17 | Apr 8, 2021 | clinicaltrials |
| NCT01915602 | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 14 | BayerINDUSTRY | 21 | Apr 8, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03389126 | Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment(AvelumabHCC) | completed | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01972672 | The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 70 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01246986 | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | completed | Phase 2 | 204 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 12, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01687673 | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT01264705 | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | completed | Phase 1 / Phase 2 | 47 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02658019 | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 29 | Lynn Feun, MDOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03380130 | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC(NASIR-HCC) | completed | Phase 2 | 41 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01935700 | Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma | completed | Phase 2 | 15 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | completed | Phase 1 / Phase 2 | 27 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01775501 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02716766 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03578874 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | completed | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2022source: clinicaltrials